1Q FY25 results update
Zip delivers strong Group Cash EBTDA result driven by outstanding US
momentum and growth
Zip Co Limited (ASX: ZIP) (“Zip”, or the “Company”) today announced its results for the quarter
ending 30 September 2024 (“1Q25”).
Zip achieved Group Cash EBTDA of $31.7m (up 233.7% vs 1Q24), driven by a particularly strong
performance in the US business. Zip US delivered Total Transaction Volume (“TTV”) of US$1,301.8m
up 42.8% vs 1Q24 and revenue of US$92.1m, an increase of 43.9% vs 1Q24.
1Q25 FINANCIAL HIGHLIGHTS
● Group Cash EBTDA of $31.7m (up 233.7% vs 1Q24)
● TTV of $2.8b (up 22.8% vs 1Q24)
● Revenue of $239.9m (up 18.8% vs 1Q24)
● Revenue margin of 8.5% (vs 8.8% in 1Q24)
● Transactions of 21.3m (up 18.1% vs 1Q24)
● Net bad debts approximately 1.6% of TTV (vs 1.9% of TTV in 1Q24)
● Cash transaction margin of 3.9% (vs 3.6% in 1Q24)
● Active customers at quarter end of 6.08m (up 1.1% vs 4Q24)
● Merchants on Zip’s platforms increased to 80.1k (up 7.0% vs 1Q24), including Cathay Pacific in
ANZ and GameStop, Major League Baseball Ticketing via Tickets.com and Major League
Baseball Shop in the US
● Zip US delivered very strong TTV performance of US$1,301.8m, up 42.8% vs 1Q24 and
revenue of US$92.1m, an increase of 43.9% vs 1Q24
● US active customers increased YoY (vs 1Q24) and QoQ (vs 4Q24) underpinned by customer
demand for the App and initiatives to drive brand and customer awareness in the US
market
● Zip AU continued to deliver improved portfolio yield which increased to 19.2% and excess
spread to 6.9% in September 2024
● Repaid all existing corporate debt through the successful execution of a fully underwritten
equity placement and Share Purchase Plan (“S
- Forums
- ASX - By Stock
- ZIP
- Zip Q1 results
ZIP
zip co limited..
Add to My Watchlist
2.71%
!
$3.03

Zip Q1 results
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$3.03 |
Change
0.080(2.71%) |
Mkt cap ! $3.916B |
Open | High | Low | Value | Volume |
$2.98 | $3.05 | $2.92 | $73.33M | 24.56M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 152664 | $3.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.03 | 126882 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 18000 | 3.020 |
1 | 5600 | 3.010 |
3 | 30537 | 3.000 |
2 | 10170 | 2.990 |
1 | 33553 | 2.980 |
Price($) | Vol. | No. |
---|---|---|
3.030 | 2500 | 1 |
3.050 | 40386 | 17 |
3.060 | 29688 | 7 |
3.070 | 16200 | 5 |
3.080 | 130900 | 6 |
Last trade - 16.17pm 27/06/2025 (20 minute delay) ? |
Featured News
ZIP (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online